Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intercept Pharmaceuticals (Nasdaq:ICPT) has announced that Jerry Durso, President and CEO, will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq:ICPT) has announced that Jerry Durso, President and CEO, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. The event will be available via a live webcast on the investor page of Intercept’s website, with an audio archive accessible for two weeks following the event.
Intercept focuses on developing therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was +13.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.
A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Source: Intercept Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.